We established an in vitro model t o study the influence of ifosfamide treatment on intracellular glutathione (GSH) levels in activated human effector cells with specific phenotypes and immunologic functions. Besides its role as the major intracellular reductant, GSH has been shown t o affect the initiation and progression of lymphocyte activation after stimulation with lectins.
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2124 restricted CTL t o lyse their specific allogeneic target cells was substantially reduced by preincubation of the effector cells with 4-OH-IF. This inhibition of the lytic activity in CD3' CTL correlated with a substantial depletion of the intracellular GSH levels in this population. Rapid reconstitution of depleted GSH levels and restoration of cytotoxic activity of CTL was achieved by incubation of the effector cells with thiols, eg, glutathione ester (GSH-ester) or 2-mercaptoethanesulfonate (mesna). (2) In contrast, the lytic activity in CD3-NK cells was not substantially affected (up to 100 pmol/L 4-OH-IF). This result correlates with the capacity of NK cells t o maintain their intracellular GSH levels after an ifosfamide treatment. (3) In comparison with CD3' CTL, CD3-NK cells are more resistant t o an ifosfamide treatment because they have higher initial GSH levels and a more than fourfold higher relative rate of GSH synthesis. 0 7995 by The American Society of Hematology.
detoxification, DNA and protein synthesis, transport, enzyme activation, protection from oxidative damage, and maintenance of cellular redox potential." In lymphocytes a GSH depletion has been shown to cause a decreased proliferative activity in these cell^,^^"^ because lymphocytes require GSH for progression from G1 into S p h a~e . '~. '~ Our previous results demonstrate that unstimulated human PBL are sensitive to an ifosfamide treatment, undergoing a depletion of GSH and also phosphorylation of small heat shock protein^.','^ The aim of this study was to analyze the effects of 4-OH-IF on immunologic functions such as proliferative capacity and cytotoxic activity of stimulated lymphocyte subpopulations [CD3-natural killer (NK) cells and CD3+ cytotoxic T lymphocyte (CTL) effector cells], which could play a role as an antitumor therapy. Accordingly, the GSH levels of both effector cell populations separately were measured after 4-OH-IF treatment. The effects were compared with an Lbuthionine-S,R-sulfoximine (BSO) treatment, which is known to markedly decrease GSH content by blocking the y-glutamyl-cysteine synthetase."
MATERIALS AND METHODS

Cells and cell culture.
Peripheral blood obtained from healthy human volunteers was anticoagulated with Heparin Novo (Novo Nordisk Pharma GmbH, Mainz, FRG). Peripheral blood mononuclear cells (PBMC) were obtained after density gradient centrifugation on Ficoll Isopaque (Pharmacia, Freiburg, FRG). After monocyte depletion, peripheral blood lymphocytes (PBL) of HLA-different donors (donors I through 8) were HLA-typed according to the established method of Terasaki and McClelland," as follows: donor I : A2, B60(40), B62(15), Bw6, Cw3, DR4, DR13(6), DQ6(1), DQ8(3). DR52, DR53; donor 2: A3. AI I , B35, B39 (16) Treatments. Monocyte-depleted PBMC of HLA-different donors were separated into CD3+ and a CD3-cell populations by selection via cell adhesion of NK cells to plastic in interleukin-2 (IL-2) medium after a 12-hour incubation
The purity of each of these cell fractions separately, as determined by FACScan analysis using a CD3 monoclonal antibody (MoAb; described below), was more than 95% (data not shown). The CD3-cell populations were incubated with recombinant IL-2 (Euro Cetus, Frankfurt, FRG) at a final concentration of 100 IU/mL RPMI 1640 medium supplemented with 10% FCS, 6 mmoUL L-glutamine, and antibiotics for another 5 days. The allospecific CD3+ cell populations were generated using irradiated (40 Gy) allogeneic B-LCL for stimulation. The cells were cultured under the same conditions as described for the NK cell populations for 5 days. As effector cells, PBL derived from donors 1, 2, and 3 were used; as stimulator cells, irradiated PBL derived from donor 6 were used.
The prodrug 4-OOH-IF (provided by ASTA-Medica, Frankfurt, FRG) rapidly gives rise to equivalent amounts of 4-OH-IF after dissolution in phosphate-buffered saline (PBS; pH 7.4).' Activated PBL (either unseparated or separated into CD3' and a CD3-cell population) were treated with 4-OH-IF or with BSO at different concentrations and incubation periods: 0, 25, 50, and 100 pmol/L of 4-OH-IF at 37°C for 1 hour; or 0, I, 2.5, 5, and 10 mmol/L of BSO at 31°C for 24 hours.
Untreated or treated cells were incubated with the thiols GSH monoethyl-(glycyl)-ester (GSH-ester; Bachem, Heidelberg, FRG) or 2-mercaptoethanesulfonate (mesna; ASTA-Medica), each at a final concentration of 0.4 mmol/L, for 6 hours before an assay.
Indirect immunojuorescence and FACScan analysis. For indirect immunofluorescence, viable (trypan blue-negative) cells (0.5 X IO6) were incubated with the following primary antibodies, each containing sodium azide, at 4°C for 1 hour: MPCl1 (IgG2b, directed against mouse-specific tumor antigens was used as a negative control MoAb), W6132 [IgG2a, anti-major histocompatibility complex (MHC) class I], anti-CD3 (IgGZa), anti-CD4 (IgGl), anti-CD8 (IgGl), anti-CD16 (IgG2a). and anti-CD56 (IgG1) (Dianova, Hamburg, FRG). After staining of the cells with a second fluorescein isothiocyanate (FITC)-conjugated rabbit antimouse Ig antibody (DAKO, Hamburg, FRG) at 4°C for 30 minutes, a quantitative flow cytometry was performed using a FACScan instrument (Becton Dickinson, Heidelberg, FRG).
Proliferation assay.
The proliferative capacity of either untreated or pretreated cells was measured in a standard [3H]-thymidine uptake assay." Activated, viable (trypan-blue negative) PBL (2 X lO'/mL) were resuspended in supplemented medium (200 pL per well) containing 100 IU IL-2 per milliliter and seeded into a 96-well flat-bottom microtiter plate (Greiner, Niirtingen, FRG). Cells were incubated at 37°C for 2 hours. Subsequently, ['HI-thymidine (1 KCi per well) was added, and the incorporation was determined after an 18-hour incubation period at 37°C in a liquid scintillation counter (Beckmann Instruments, Munich, FRG).
Determination of intracellular GSH. Total soluble intracellular GSH (reduced and oxidized form) of activated effector cells either untreated or treated was quantified using a modified high performance liquid chromatography (HPLC) as previously described by Issels and Nagele.'' The cell pellet was treated with l N perchloric acid, and y-glutamylglutamate was added as an internal standard. After derivatization of the free thiol groups with iodoacetic acid and of the amino groups with l-Auoro-2,4-dinitrobenzene, the reaction mixtures were separated by HPLC. Aliquots were injected onto pBondapak amine column (4 X 250 mm; Waters, Eschborn, FRG) and eluted with a sodium acetate gradient (flow rate, 2 mL/ min) in a water:methanol:acetic acid solvent at pH 4.5. The dinitrophenyl derivatives were detected at 360 nm. GSH was quantified in relation to the internal standard. Protein was determined according to the method of Lowry.*'"
Measurement of [3sS]-cysteine incorporated into GSH. Cells ( 5 X lo6) were incubated in McCoy's 5A medium without cysteine, methionine, or glutathione. Then 0.2 mmol/L [35S]-cysteine (150 mCi/mmol; Amersham, Braunschweig, FRG) was added to the cells, which were incubated at 37°C for 3 hours. The cells were then washed and prepared for GSH analysis as described above. Fractions of the HPLC effluent were collected at l-minute time intervals. The amount of radioactivity in the collected fractions was measured by a liquid scintillation counter (Beckman Instruments). The identity of the radioactive peaks was checked by exact correspondence to prepared standards, as previously de~cribed.'~ Cystine, cysteine, GSH, and GSSG (oxidized GSH) were clearly distinguished by the retention times of 6. I , 11.3, 26.4, and 31 .S minutes, respectively.
"Chromium release assay.
The specificity of the CD3' and CD3-separated effector cell populations was monitored in a standard 4-hour "chromium (5'Cr) release (CML) assay." The following target cells (3 X 10' cells per well) were incubated for 1 hour at 37°C with 5% CO2 in the presence of "Cr (0.01 mCi/mL; NENDupont, Bad Homburg, FRG): allogeneic B-LCL and K562 cells and a human chronic myelogenous leukemia cell line (CCL 243; ATCC). Each effector cell population, either untreated or pretreated (with ifosfamide or ifosfamide plus GSH-ester), was coincubated with the target cells at 37°C for 4 hours in round-bottom microtiter plates (Greiner) in a total volume of 200 pL supplemented medium per well at varying effector to target (E:T) ratios ranging from 40: 1 to 2.5: 1. The percentage of specific cytotoxicity was calculated using the following formula: [(experimental release minus spontaneous release)/(maximum release minus spontaneous release)] X 100. Spontaneous release of all target cells was always less than 10%. were performed. Cell surface expression of MHC class I molecules determined with W6132 MoAb and T-cell (anti-CD3, anti-CD4, and anti-CD8 MoAbs) and NK-cell surface markers (anti-CD16 and anti-CD56 MoAbs) on untreated and ifosfamide-treated effector cells were compared. Despite the observed reduction in the proliferative activity of the 4-OH-IF-treated effector cells, the relationship of lymphocyte subsets was not influenced immediately after treatment (day 0) or at the time of the proliferation assay (day 4; Table 1 ). However, the loss of proliferative capacity correlated with a substantial decrease of the total intracellular GSH level (reduced as well as oxidized form) of the effector cells from 23 nmolhg protein to 3 nmol1mg protein after treatment with I O 0 ymol/L of 4-OH-IF for 1 hour, as indicated in Fig  1A. Comparable results were obtained by a BSO treatment of the cells (Fig IC) . An incubation of activated lymphocytes with 10 mmol/L BSO for 24 hours led to reduction of the intracellular GSH level from 23 nmolhg protein to I nmoV mg protein.
RESULTS
The
As shown in Fig 1B and D , the decreased GSH levels after depletion with 4-OH-IF or with BSO could be restored up to initial levels by incubation of the cells with exogenous GSH-ester at a concentration of 0.4 mmoVL for 6 hours. As GSH alone is not efficiently transported into many cell types, including lymphocytes:' we used the monoethyl-(glycyl)-ester of GSH, which is well transported and intracellularly hydrolyzed to GSH?'.*' Similar results were obtained by using the thiol mesna for reconstitution of the GSH level (data not shown). The proliferative activity of activated lymphocytes was only restored after a GSH depletion with BSO (Fig ID) but not after treatment with 4-OH-IF (Fig IB) .
To study the effects of an ifosfamide treatment on the cytotoxic activity of different lymphocyte subsets, IL-2-stimulated mixed effector lymphocyte populations were sep- arated into a CD3+ CTL and a CD3-NK cell fraction. Each cell fraction was incubated separately with different concentrations of 4-OH-IF, and then CML assays were performed to test the cytotoxic capacity. The purity of each cell fraction was greater than 95% as determined by FACScan analysis using T cell-specific (anti-CD3, anti-CD4, and anti-CD8) and NK cell-specific (anti-CD16 and anti-CD56) MoAbs (data not shown). As target cells, allogeneic EBV-transformed B-LCL (CTL target cells) and K562 cells (NK target cells) were used. The lysis of allogeneic B-LCL target cells (no HLA antigen is shared between effector and target cells) was mediated only by the CD3+ CTL population but not by the CD3-NK cells (Fig 2A) , whereas the lysis of K562 NK target cells was mediated only by the CD3-NK cell population (Fig 2B) . After incubation of both effector cell populations separately with different concentrations of 4-OH-IF (0, 25, 50, and 100 pmol/L 4-OH-IF for 1 hour), the lysis of the allogeneic target cells (B-LCL) was substantially reduced in a dose-dependent manner by 4-OH-IF treatment of CD3+ CTL (Fig 2C) . In contrast, the lysis of NK target cells (K562) was only inhibited after incubation of the CD3-NK cell population at high (100 pmol/L) 4-OH-IF concentrations (Fig 2D) . These functional differences could be correlated with differential effects of a 4-OH-IF treatment on the intracellular GSH level of CD3+ CTL and CD3-NK cells. As shown in Table 2 , concomitant with the loss of lytic activity, the intracellular GSH level of the 4-OH-IF-treated CD3+ CTL effector cells was found to be substantially reduced. A reduction of the GSH level down to approximately 50% of the initial GSH level in the CTL population was achieved by incubation of these cells with 25 pmol/L 4-OH-IF for 1 hour. In contrast, to achieve an equal reduction in the GSH level in NK cells, a concentration of 100 p m o K 4-OH-IF for 1 hour was necessary.
The GSH-depleted, ifosfamide-preincubated CD3+ CTL effector cell population showed rapid restoration of the intracellular GSH level up to initial levels after incubation of the cells with 0.4 mmol/L GSH-ester for 6 hours at 37°C (Table  2) . Similar results were obtained with the thiol mesna under identical conditions (data not shown). Next, we investigated whether reconstitution of the GSH levels in CD3+ CTL and CD3-NK effector cells after 4-OH-IF treatment leads to a recovery of the cytotoxic activity. The results of CML assays are shown in Fig 3. Interestingly, the cytotoxic activity against allogeneic B-LCL (Fig 3A) or K562 as NK target cells (Fig 3B) of ifosfamide-treated CD3+ CTL (50 pmol/L 4-OH-IF) and CD3-NK (100 pmol/L 4-OH-IF) effector cells was completely restored after the intracellular GSH level was reconstituted up to initial levels by incubation with exogenous GSH-ester ( Table 2) . Similar results were obtained if the effector cells were incubated with the thiol mesna (data not shown).
The different effects of ifosfamide on NK cells and CTL may be caused by a different capacity of the cells to synthesize GSH. In comparison to CD3+ CTL, CD3-NK cells have significantly ( P < .OS) higher initial GSH levels ( Table   2 , first line). However, for the differential effects of a 4-OH-IF treatment on the GSH levels in different cells, an increased capacity of GSH synthesis may be as important or even more important in promoting the resistance to 4-OH-IF than the intracellular levels of GSH.29 Therefore, we determined the relative rate of GSH synthesis. The GSH synthesis in mammalian cells is limited by the availability of the precursor amino acid cysteine. For quantification of newly synthesized GSH, radiolabeled [35S]-cysteine was used as a tracer. As shown in Fig 4A, the relative rate of GSH synthesis in CD3-NK cells is more than fourfold greater than in CD3+ CTL (Fig 4A, open bars) . The corresponding intracellular GSH levels of CTL and NK cells are indicated (Fig 4A, hatched  bars) .
The substantially higher rate of GSH synthesis in NK cells was preserved even after a reduction of the initial GSH levels with 4-OH-IF (Fig 4B) . A 50% reduction of the initial GSH levels was achieved in CTL by treatment with 25 pmol/L 4-OH-IF (27.2 to 13.0 nmol of GSH per milligram of protein); in contrast, NK cells must be treated with 100 pmoV L 4-OH-IF to obtain an approximately equal reduction in the GSH levels (36.5 to 16.8 nmoVmg protein).
DISCUSSION
Activated ifosfamide (4-OH-IF) has been shown to be one of the most effective antineoplastic agents for the treatment of solid turn or^.'.^ In addition to the cytostatic efficacy of oxazaphosphorines, it is known that 4-OH-IF itself6.' andor its toxic metabolites4 cause a depletion of the intracellular GSH levels in different cell types. Several biochemical reactions exist that are able to reduce the toxicity of oxazaphosphorines in different cell types; eg, activated cyclophosphamide or ifosfamide can be oxidized by aldehyde dehydrogenases into inactive metabolite^.^.^' It has been demonstrated that 4-OH-IF leads to a depletion of GSH in lymphocytes in vitro6.' and in vivo.6 GSH, the major intracellular nonprotein thiol compound, very efficiently protects cells against oxazaphosph~rines~~'~~~'~~~ by conjugation of GSH to toxic metabolites of the oxazaphosphorines.' This conjugate formation results in a reduction of the intracellular GSH level. GSH has been shown to become rate-limiting to lymphocyte functions, such as proliferation and cytotoxic 
. . . Results are expressed as percent specific lysis at varying E:T ratios ranging from 40:l to 2.51. Each data point represents the mean value of independent experiments with three HLA-different effector cell populations (donors 1, 2, and 3; described in Materials and Methods); +SD for each data point was always less than 10%.
activity.".34 Also, the proliferation of mitogen-stimulated lymphocytes is dependent on the availability of GSH.'"'6*'5,36 In accordance with these observations, our data demonstrate a reduction in the proliferative capacity of IL-2-activated human lymphocytes after GSH depletion using BSO. Furthermore, we were able to show a reconstitution of the intracellular GSH levels of BSO-pretreated cells using different exogenous thiols (eg, GSH-ester or mesna) that could be correlated with an increased proliferative response. Therefore, we conclude that the intracellular GSH level is relevant for the proliferative capacity of activated lymphocytes. Similar to the effects of BSO on the GSH level of stimulated lymphocytes, 4-OH-IF was able to reduce the intracellular GSH level as well as the proliferative capacity. However, despite the reconstitution of the intracellular GSH level of ifosfamide-pretreated cells using thiols, a reconstitution of the proliferative activity of these cells was not possible. This finding is not surprising, because 4-OH-IF irreversibly inhibits cell proliferation by alkylation of nucleophilic centers of biomolecules,' which can lead to DNA interstrand crosslinks, DNA protein crosslinks, and DNA single-strand breaks.j2 As previously shown by Yim et al,33 intracellular GSH levels do not only affect cell proliferation but also affect cytotoxic activity of mouse-derived lymphokine-activated killer (LAK) cells. In rats, immunocompetence is also impaired with in vivo GSH defi~iency.~' The aim of this study was to analyze the effects of an ifosfamide treatment on the cytotoxic activity and GSH levels of separated human CD3' CTL and CD3.-NK effector cell populations. The data presented here show that the proliferative activity of unseparated human lymphocytes against IL-2 is reduced after an ifosfamide treatment. With regard to the results obtained by cell surface analysis of either untreated or 4-OH-IF-treated effector cells, a selective elimination of a specific lymphocyte subset due to direct cytotoxic effect of activated ifosfamide can be excluded, because the composition of the major lymphocyte subpopulations (CD4 T helper cells, CD8 cytotoxic T cells, and NK cells) was not modulated. The observed reduction of proliferative activity correlated with a dose-dependent depletion in the intracellular GSH levels in mixed lymphocyte populations. Previously it was shown that subsets of human PBMC differ substantially in mean GSH levels3' and that the GSH levels regulate IL-2 action on cytotoxic
We determined the cytotoxic activity of allospecific CD3+ CTL and CD3-NK effector We show that the cytotoxic activity and also the GSH level of non-MHC-restricted NK cells are much more resistant to an ifosfamide treatment compared with CTL (ie, a twofold reduction in the intracellular GSH level of CTL is obtained by 25 pmol/L 4-OH-IF). To achieve an equal reduction in the GSH levels of NK cells, the 4-OH-IF concentration must be elevated more than fourfold (100 pmol/L 4-OH-IF), while lower 4-OH-IF concentrations have only minor effects on GSH level and lytic activity of NK cells. To address the question of how NK cells resist an ifosfamide treatment better than CTL, the initial GSH levels of NK cells and CTL from a panel of HLA-different blood donors were determined. A comparison of intracellular GSH levels of both cell populations separately shows significantly higher initial GSH levels for NK cells ( P < .05). However, this difference in initial GSH levels in NK cells compared with CTL is about 1.5-fold, whereas the resistance against an 4-OH-IF treatment that leads to an equal GSH depletion in both cell types was about fourfold. To analyze this discrepancy, the relative rate of GSH synthesis in NK cells and CTL was compared. In general, lymphocytes are known to depend on endogenous GSH synthesis because they cannot import GSH directly.26 The tripeptide GSH is synthesized in a two-step pathway: the first reaction involves y-glutamylcysteine synthetase. This reaction is rate-limiting for GSH synthesis and under feedback inhibition by GSH." The limiting compound for the synthesis of GSH is cysteine, which cannot be synthesized by most cell types. We were able to show that NK cells have a significantly higher capacity for GSH synthesis than CTL. Furthermore, this ratio is preserved after equal GSH depletion by 4-OH-IF. Transport of cysteine and cystine into the cell is mediated by several transport systems.39 It is known that the transport systems can vary considerably among different cell types; eg, macrophages have a high transport activity for cystine, while this transport system is extremely weak in T cell^?"^^' Whether substantial differences in cysteinekystine transport systems exist between CTL and NK cells as well is currently under investigation in our laboratory.
CD3+ effector cells
CD3-effector cells
The finding that GSH deficiency can be rescued by thiols suggests that thiols might also restore the cytotoxic activity MULTHOFF ET AL of GSH-depleted CTL. Indeed, in this study we were able to demonstrate that reduced CTL functions and GSH deficiency could be restored using thiols (eg, mesna). The thiol mesna, which is routineously applied during ifosfamide chemotherapy in vivo primarily as an uroprotective agent: might also have beneficial effects on immunologically relevant effector cells. More generally, the maintenance of normal GSH levels in CD3' CTL and CD3-NK cells of cancer patients treated with oxazaphosphorine therapy may be of clinical importance with regard to their immunocompetence.
